No Data
No Data
We Think Asymchem Laboratories (Tianjin) (SZSE:002821) Can Stay On Top Of Its Debt
Asymchem Laboratories (06821): 0.05754 million restricted shares will be listed and traded from August 27th.
Asymchem Laboratories (06821) announced the release of a portion of the reserved grants for the 2020 restricted stock incentive plan.
Hong Kong stock market anomaly | Asymchem Laboratories (06821) fell more than 4%, leading the CRO concept. The industry's performance is generally under pressure due to the decline in investment and financing in the pharmaceutical industry.
CRO concept stocks fell today. As of press time, Asymchem Laboratories (06821) fell 3.74%, at HKD 39.9; Tigermed (03347) fell 3.67%, at HKD 30.2; Pharmaron (03759) fell 3.06%, at HKD 8.55; Wuxi AppTec (02359) fell 2.88%, at HKD 32.05.
Sinolink: The results of the negotiations on drug prices in the United States have been announced, and the continuous procurement of medical devices domestically is ongoing.
Bullish on the development of the domestic medical devices industry in the second half of the year, with the industry's purchasing demand expected to accelerate recovery. At the same time, domestic leading companies in sub-sectors such as ultrasound and endoscopy, due to their strong competitiveness, are expected to further increase market share, with sales growth and profitability expected to return to an upward trend.
Asymchem Laboratories plans to repurchase and cancel 1680 restricted A-share stocks.
Asymchem Laboratories (06821) issued an announcement that on August 16, 2024, the board of directors held the 55th meeting of the fourth session to approve the proposal on repurchasing and canceling part of the restricted stocks of the 2020 restricted stock incentive plan. They agreed to repurchase and cancel the 1680 A-share restricted stocks that were reserved for and awarded to Sun Xuehui, a departed incentive object who has not yet released the restriction.
Asymchem Approves Share Repurchase and Cancellation
No Data